Overview A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors Status: Not yet recruiting Trial end date: 2024-12-30 Target enrollment: Participant gender: Summary This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study. Phase: Phase 1/Phase 2 Details Lead Sponsor: Maxinovel Pty., Ltd.